S 117957

Drug Profile

S 117957

Alternative Names: S-117957; V-117957

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Purdue Pharma; Shionogi
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Insomnia
  • Discontinued Dental pain; Neuropathic pain

Most Recent Events

  • 03 Dec 2013 Suspended - Phase-II for Dental pain in USA (PO)
  • 03 Dec 2013 Purdue Pharma terminates a phase II trial in Dental pain in USA (NCT01900795)
  • 31 Jul 2013 Phase II clinical trials for Dental pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top